Clinical Updates for the Optimal Management of Patients with Inflammatory Bowel Disease

Program Dates: January 10, 2020 - January 9, 2021
Credits: 1.0 AMA PRA Category 1 Credit™

Clinical Updates for the Optimal Management of Patients with Inflammatory Bowel Disease

Program Overview

This CME activity will review recent advances in the management of patients with Inflammatory Bowel Disease (IBD) as presented at the Digestive Disease Week (DDW) 2019 in San Diego, CA. The expert faculty will discuss the science of the inflammatory cascade as well as review recent clinical trial data for IBD treatments. The faculty will also discuss strategies for utilizing and collaborating with the interprofessional team to optimize patient outcomes and quality of life concerns.  Upon completion of this activity, learners will gain insight into current treatment and management techniques, ultimately improving patient care.

Target Audience

Gastroenterologists, primary care physicians, nurses, NPs, PAs, and other members of an interprofessional care team involved in the management of inflammatory bowel disease.

Learning Objectives

  1. Understand the science of the inflammatory cascade in IBD.
  2. Analyze the most recent clinical data for current and emerging IBD treatments.
  3. Collaborate with the healthcare team to address quality of life issues and optimize outcomes for patients with IBD.


David P. Hudesman, MD
Associate Professor, Department of Medicine
Medical Director, Inflammatory Bowel Disease Center
NYU Langone Health
New York, NY

Dana Lukin, MD
Assistant Attending Immunologist
New York Presbyterian Hospital
Assistant Professor of Clinical Medicine
Weill Cornell Medical College, Cornell University
New York, NY


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
David P. Hudesman, MD


Consultant/Advisor: Pfizer Inc., Takeda Pharmaceutical Co., Ltd., Jansenn Pharmaceutica, AbbVie, Salix Pharmaceuticals, Inc.

Grant/Research Support: Pfizer Inc.


Dana Lukin, MD


Consultant/Advisor: AbbVie, Abgenomics International Inc., Pfizer Inc., Takeda Pharmaceutical Co., Ltd., Celgene Corp., Prometheus Laboratories Inc.

Grant/Research Support: Abbvie, Takeda Pharmaceutical Co., Ltd.

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski; and Devon Dietzel hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Screen Shot 2018-12-11 at 12.19.42 PM

Credit Designation Statements

AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 CreditTM.

Financial Support

This activity has been supported by an independent educational grant from Celgene Corporation and Shire Plc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Celgene Corporation and Shire Plc. do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].


Provided by: AcademicCME-web

Leave a Reply

Your email address will not be published. Required fields are marked *